8-K: Elevance Health Reports Q3 2025 Results

Elevance Health reports third quarter 2025 results in line with expectations, driven by revenue growth and strategic investments despite Medicaid membership losses.

Summary

• Operating revenue for the third quarter of 2025 was $50.1 billion, an increase of 12.0% from the prior year quarter.
• Diluted EPS for Q3 2025 was $5.32, while adjusted diluted EPS was $6.03.
• The company reaffirmed its full-year 2025 benefit expense ratio guidance of approximately 90.0% and adjusted diluted EPS guidance of approximately $30.00.
• Elevance Health returned $3.3 billion of capital to shareholders year-to-date.
• Operating cash flow year-to-date was $4.2 billion, representing 0.8 times GAAP net income, a decrease of $0.9 billion year-over-year, partly due to a Provider Settlement Agreement payment.
• Medical membership totaled approximately 45.4 million as of September 30, 2025, a decrease of 0.9% year-over-year, primarily due to lower BlueCard and ongoing Medicaid membership losses.
• The benefit expense ratio was 91.3%, an increase of 180 basis points year-over-year, reflecting elevated, but expected, cost trends in the Medicare business due to changes in the Inflation Reduction Act.
• The operating expense ratio improved by 130 basis points to 10.5%, while the adjusted operating expense ratio increased by 100 basis points to 10.4%, driven by targeted investments in Carelon's capabilities, workforce, and technology adoption.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While operating revenue and diluted EPS showed strong growth, adjusted operating gain and adjusted diluted EPS declined. The benefit expense ratio increased due to expected Medicare Part D costs. However, the company reaffirmed its full-year guidance, indicating results were within expectations, and continues strategic investments and significant share repurchases, signaling confidence in future performance despite some headwinds like Medicaid membership losses and a one-time settlement payment impacting cash flow.

Positives

• Operating revenue increased by 12.0% to $50.1 billion in Q3 2025, driven by higher premium yields, recent acquisitions, and Medicare Advantage membership growth.
• Diluted EPS increased by 22.0% to $5.32 in Q3 2025.
• The operating expense ratio improved by 130 basis points to 10.5% in Q3 2025.
• Carelon segment operating revenue grew by 33% to $18.3 billion, fueled by recent acquisitions in home health and pharmacy services, and growth in CarelonRx product revenue.
• Carelon Services operating gain increased by 19.0% to $219 million in Q3 2025.
• Medicare Advantage membership grew by 9.7% year-over-year.
• The company repurchased 2.9 million shares of its common stock for $875 million in Q3 2025.
• Approximately $7.2 billion of Board-approved share repurchase authorization remains as of September 30, 2025.

Negatives

• Operating gain decreased by 8.0% to $1.3 billion in Q3 2025.
• Adjusted operating gain decreased by 45.3% to $1.344 billion in Q3 2025.
• Operating margin decreased from 3.1% in Q3 2024 to 2.6% in Q3 2025.
• Adjusted diluted EPS decreased from $8.60 in Q3 2024 to $6.03 in Q3 2025.
• The benefit expense ratio increased by 180 basis points to 91.3% in Q3 2025, reflecting elevated costs in Medicare Part D.
• Operating cash flow year-to-date decreased by $0.9 billion year-over-year to $4.2 billion, impacted by the Provider Settlement Agreement payment.
• Medical membership decreased by 0.9% year-over-year, primarily due to lower BlueCard and ongoing Medicaid membership losses from eligibility reverifications.
• Health Benefits segment operating gain decreased by 62.5% to $0.6 billion in Q3 2025, impacted by higher medical cost trends and increased investments.
• CarelonRx operating gain decreased by 10.2% to $556 million in Q3 2025.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment.
• Ability to secure and implement sufficient premium rates.
• Impact of large-scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes.
• Impact of new or changes in existing federal, state, and international laws or regulations, including those impacting healthcare, insurance, and pharmacy services.
• Impact of cyber-attacks or other privacy or data security incidents, or failure to comply with related laws or regulations.
• Failure to effectively maintain and modernize information systems, or failure of information systems or technology, including artificial intelligence, to operate as intended.
• Failure to effectively maintain the availability and integrity of data.
• Changes in economic and market conditions, as well as regulations that may negatively affect liquidity and investment portfolios.
• Competitive pressures and the ability to adapt to industry changes and develop and implement strategic growth opportunities.
• Risks and uncertainties regarding Medicare and Medicaid programs, including non-compliance with complex regulations.
• Ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks.
• A negative change in healthcare product mix.
• Costs and other liabilities associated with litigation, government investigations, audits, or reviews.
• Ability to contract with providers on cost-effective and competitive terms.
• Risks associated with providing healthcare, pharmacy, and other diversified products and services, including medical malpractice or professional liability claims and non-compliance with the pharmacy services agreement with CaremarkPCS Health, L.L.C.
• Effects of any negative publicity related to the health benefits industry in general or the company in particular.
• Risks associated with mergers, acquisitions, joint ventures, and strategic alliances.
• Possible impairment of the value of intangible assets if future results do not adequately support goodwill and other intangible assets.
• Possible restrictions in the payment of dividends from subsidiaries and increases in required minimum levels of capital.
• Ability to repurchase shares of common stock and pay dividends due to the adequacy of cash flow and earnings and other considerations.
• Potential negative effect from a substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact access to or further increase the cost of financing.
• A downgrade in financial strength ratings.
• Events that may negatively affect licenses with the Blue Cross and Blue Shield Association.
• Intense competition to attract and retain employees.
• Risks associated with international operations.
• Various laws and provisions in governing documents that may prevent or discourage takeovers and business combinations.

Future Outlook

Elevance Health reaffirmed its full-year 2025 benefit expense ratio guidance of approximately 90.0% and adjusted diluted EPS guidance of approximately $30.00. The company is focused on advancing affordability and elevating the member experience through growing value-based care partnerships and AI-enabled digital solutions that simplify access and improve outcomes. For 2026, the company plans to remain disciplined in managing controllable factors to position its businesses for long-term, sustainable growth and value creation for all stakeholders.

Management Comments

• "Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health."
• "In a dynamic healthcare environment, we're focused on advancing affordability and elevating the member experience through our growing value-based care partnerships and AI-enabled digital solutions that simplify access and improve outcomes."
• "As we plan for 2026, we remain disciplined in managing what we can control – positioning our businesses for long-term, sustainable growth and value creation for all stakeholders." Gail K. Boudreaux, President and Chief Executive Officer

Industry Context

Elevance Health operates within a dynamic healthcare environment, navigating trends in healthcare costs and utilization rates, and adapting to evolving federal, state, and international regulations. The company's strategic focus on value-based care partnerships and AI-enabled digital solutions aligns with broader industry shifts towards enhancing cost efficiency, improving patient outcomes, and leveraging technological innovation in healthcare delivery. The reported increase in the benefit expense ratio is partly attributed to pronounced seasonality in Medicare Part D benefits, influenced by changes introduced in the Inflation Reduction Act, highlighting the direct impact of specific regulatory changes on the company's financial performance within the healthcare sector.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Operating cash flow year-to-date decreased in part due to the Provider Settlement Agreement payment for the multi-district BCBSA litigation.
• Risks include costs and other liabilities associated with litigation, government investigations, audits, or reviews.

Stakeholder Impact

• Shareholders: Benefit from continued dividend payments ($1.71/share) and significant share repurchases ($875 million in Q3 2025), with a remaining $7.2 billion authorization, indicating a commitment to shareholder returns. Reaffirmed FY2025 guidance provides clarity on expected performance.
• Members/Consumers: The company's focus on improving affordability and elevating the member experience through value-based care and AI-enabled digital solutions aims to enhance their access to care and outcomes.
• Employees: The company is making increased investments to support and strengthen its workforce.
• Providers: The company's ability to contract with providers on cost-effective and competitive terms is identified as a risk factor, potentially impacting provider relationships and network stability.
• Creditors: The substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact access to or further increase the cost of financing are noted risks, which could affect the company's credit profile.

Next Steps

• Management will host a conference call and webcast on October 21, 2025, at 8:30 a.m. EDT to discuss the company's third quarter results and outlook.
• The fourth quarter 2025 dividend of $1.71 per share is payable on December 19, 2025, to shareholders of record at the close of business on December 5, 2025.
• The company is planning for 2026, focusing on disciplined management to position businesses for long-term, sustainable growth and value creation.

Key Dates

Recommendation

Elevance Health's Q3 2025 results present a mixed picture. While operating revenue and diluted EPS showed strong growth, adjusted operating gain and adjusted diluted EPS declined, and the benefit expense ratio increased due to expected Medicare Part D costs. The company's reaffirmation of full-year guidance suggests results were within expectations, and strategic investments in Carelon and technology, coupled with significant share repurchases, demonstrate a commitment to long-term value creation. However, ongoing Medicaid membership losses and the impact of the Provider Settlement Agreement on cash flow are notable headwinds. Given the balance of positive growth drivers and operational challenges, a 'hold' recommendation is appropriate for investors to monitor the execution of strategic initiatives and the impact of market and regulatory dynamics on future performance.

Keywords

Elevance Health, ELV, Healthcare, Health Insurance, Managed Care, Medicare Advantage, Medicaid, Carelon, CarelonRx, Q3 2025 Earnings, Financial Results, Operating Revenue, EPS, Benefit Expense Ratio, Operating Cash Flow, Share Repurchase, Digital Solutions, Value-Based Care, AI-enabled